|Day Low/High||19.81 / 20.40|
|52 Wk Low/High||16.56 / 62.70|
The company expects to resume testing an inhaled insulin device during the first quarter.
The company's earnings Thursday may take a back seat to an update on the cholesterol drug.
Pfizer will pay $1.3 billion to buy out Sanofi-Aventis' share of Exubera.
The FDA tells Pfizer it will need three more months to review the inhaled insulin application.
Cramer says that the retailer is still best of breed despite a profit warning.
Investors will key on diabetes and neuroscience franchises when the company reports Thursday.
Alfred E. Mann's company has a fierce fight in the inhaled insulin market.
Pfizer says an analysis of two clinical trials involved 304 adults with diabetes.
Competitors may gain from a quick approval for Exubera, an inhaled insulin product.
More extremely oversold Arms Index moving averages and big downside action in the markets would end the decline.
The drug giant's stock hits a one-year low, and more disappointment lurks around the bend.
The household survey offers some comfort but the FOMC's Tuesday meeting still will be the coming week's major economic event.
Biotech is usually a good place to look, as Nektar Therapeutics showed today.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.